apalutamide sold brand name erleada among others nonsteroidal antiandrogen nsaa medication used treatment prostate specifically indicated use conjunction castration treatment nonmetastatic castrationresistant prostate cancer taken side effects apalutamide added castration include fatigue nausea abdominal pain diarrhea high blood pressure rash falls bone fractures underactive rarely cause medication high potential drug apalutamide antiandrogen acts antagonist androgen receptor biological target androgens like testosterone prevents effects hormones prostate gland elsewhere apalutamide first described approved treatment prostate cancer february first medication approved specifically treatment apalutamide used conjunction castration either via bilateral orchiectomy gonadotropinreleasing hormone analogue gnrh analogue therapy method androgen deprivation therapy treatment also promising potential treatment metastatic castrationresistant prostate cancer mcrpc nsaa enzalutamide androgen synthesis inhibitor abiraterone acetate used apalutamide provided form mg oral taken dosage mg per day four tablets used treatment contraindications apalutamide include pregnancy history susceptibility apalutamide found well tolerated clinical common side effects reported added surgical medical castration including fatigue nausea abdominal pain side effects included rash falls bone fractures hypothyroidism well seizures among apalutamide expected teratogen theoretical risk birth defects male infants taken women may impair male used monotherapy ie without surgical medical castration men nsaas known produce additional estrogenic side effects like breast tenderness gynecomastia feminization general increasing estradiol similarly related secondgeneration nsaa enzalutamide unlike firstgeneration nsaas like flutamide bicalutamide elevated liver enzymes hepatotoxicity reported case reports rare interstitial lung disease apalutamide exist similarly firstgeneration nsaas known antidote overdose general supportive measures undertaken clinical toxicity diminishes apalutamide high potential drug terms effects apalutamide drugs exposure substrates udpglucuronosyltransferase pglycoprotein may reduced varying terms effects drugs apalutamide strong inhibitors may increase levels apalutamide major active metabolite ndesmethylapalutamide mild moderate inhibitors expected affect apalutamide acts selective competitive silent antagonist androgen receptor ar via ligandbinding domain hence similar structurally pharmacologically secondgeneration nsaa shows advantages including higher antiandrogenic activity well severalfold reduced central nervous system latter difference may reduce comparative risk seizures central side apalutamide greater affinity ar bicalutamide firstgeneration acquired mutation ar identified advanced prostate cancer cells found confer resistance enzalutamide newer nsaa darolutamide affected mutation found affected testedwellknown ar apalutamide may effective subset prostate cancer patients acquired resistance abiraterone apalutamide shows potent induction potential cytochrome enzymes similarly strong inducer weak inducer well inducer addition apalutamide inducer pglycoprotein apalutamide binds weakly inhibits gabaa receptor vitro similarly enzalutamide halfmaximal inhibitory concentration μm due relatively lower central concentrations may lower risk seizures apalutamide found significantly concentrationdependently increase qt mean absolute oral bioavailability apalutamide mean peak levels apalutamide occur hours following administration range food delays median time peak levels apalutamide approximately hours significant changes peak levels areaundercurve steadystate levels apalutamide achieved following weeks administration approximate peak concentrations mgday apalutamide steadystate μgml relative peak levels μgml μmoll mgday enzalutamide mean rbicalutamide levels μgml μmoll mgday mean volume distribution apalutamide steadystate approximately plasma protein binding apalutamide major metabolite ndesmethylapalutamide irrespective apalutamide metabolized liver major active metabolite ndesmethylapalutamide formed enzymes similar contribution enzymes formation following single oral dose mg apalutamide apalutamide represented ndesmethylapalutamide total areaundercurve mean elimination halflife apalutamide steadystate fluctuations apalutamide exposure low levels stable throughout day mean peaktotrough ratios apalutamide single dose apalutamide clearance rate clf lh clearance rate increased lh change considered likely due approximately apalutamide excreted urine unchanged apalutamide ndesmethylapalutamide excreted feces unchanged apalutamide apalutamide structural analogue enzalutamide pyridyl variant enzalutamide derived nonsteroidal androgen derived firstgeneration nsaa nilutamide extension flutamide nilutamide enzalutamide apalutamide apalutamide originated university california system developed primarily janssen research development division johnson first described literature united states patent application published november another submitted july march publication described discovery development phase clinical trial apalutamide completed march results study published information phase iii clinical studies including atlas spartan titan published positive results phase iii trials first described janssen submitted new drug application apalutamide united states food drug administration october apalutamide approved food drug administration united states brand name erleada treatment nmcrpc february subsequently approved canada european union apalutamide generic name drug inntooltip international nonproprietary also known developmental code names apalutamide marketed brand names erleada apalutamide available united states canada european union httpsenwikipediaorgwikiapalutamide